FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
Talphera ( TLPH ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, November 12, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations - Cormedix ( NASDAQ:CRMD )
CorMedix Inc. ( NASDAQ:CRMD ) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents. Sales reached $104.27 million, a jump from $11.5 million a year ago, beating the consensus of $86.02 million.
Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday - BigBear.ai Hldgs ( NYSE:BBAI ) , Cormedix ( NASDAQ:CRMD )
U.S. stocks were mixed, with the Dow Jones index gaining more than 300 points on Wednesday. Shares of Pharming Group N.V. ( NASDAQ:PHAR ) rose sharply during Wednesday's session after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
Strong Earnings and Biotech Resilience Define the Midweek Momentum - Humacyte ( NASDAQ:HUMA ) , Cormedix ( NASDAQ:CRMD )
DENVER, Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- After decades of failed attempts by corporate giants and research consortia across the globe, Kraig Biocraft Laboratories ( OTCQB:KBLB ) appears poised to crack biotechnology's most persistent challenge: scalable, high-performance recombinant spider ...
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
‒ Q3 2025 Net Revenue of $104.3 million. Pro Forma Net Revenue of $130.8 million ...
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates
CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.
Wall Street Analysts Predict an 80.58% Upside in CorMedix ( CRMD ) : Here's What You Should Know
The mean of analysts' price targets for CorMedix (CRMD) points to an 80.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Top Stocks With Earnings This Week: Plug, Oklo, Circle And More - Rigetti Computing ( NASDAQ:RGTI )
The pace of earnings season slows down in the days ahead, but there are still plenty of retail-favorite names set to report this week. Here's a look at the reports likely to be watched by individual investors. PLUG stock is moving. See the real-time price action here.
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
Jazz Pharmaceuticals posts strong Q3 results with higher EPS and sales, aided by a tax benefit and robust neuroscience growth.
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
Perrigo Q3 Earnings Beat, Sales Miss, Stock Falls on '25 View Cut
PRGO beats Q3 earnings estimates but misses on sales. It also trims the 2025 outlook and launches a strategic review of its infant formula unit.
Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues
FOLD's third-quarter earnings top estimates as rising Galafold and Pombiliti + Opfolda sales lift revenues by 19% year over year.
Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientific.
All You Need to Know About CorMedix ( CRMD ) Rating Upgrade to Strong Buy
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for November 4th
CRMD, GWRE, TNET, UHS and ISBA have been added to the Zacks Rank #1 (Strong Buy) List on Nov. 4, 2025.
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
BERKELEY HEIGHTS, N.J., Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- CorMedix Inc. ( Nasdaq: CRMD ) , a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the ...
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 - Cormedix ( NASDAQ:CRMD )
BERKELEY HEIGHTS, N.J., Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- CorMedix Inc. ( NASDAQ:CRMD ) , a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the ...
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down
Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
AMRN's third-quarter earnings fall short of expectations, but stronger U.S. Vascepa sales push revenues above estimates.
United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark
UTHR beats Q3 earnings forecasts on solid Tyvaso and Orenitram growth, while revenues fall shy of estimates.
RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down
Repligen posts strong Q3 results with revenue growth and an earnings beat, yet shares dip as tighter EPS guidance tempers investor optimism.
4 High-Earnings Yield Value Picks Ahead of Potential Fed Rate Cut
As the Fed readies for another rate cut, value investors could turn to high-earnings-yield stocks like AUGO, CMC, PARR and CRMD.
Cormedix Board Member Makes $275K Stock Purchase - Cormedix ( NASDAQ:CRMD )
A significant insider buy by Myron Kaplan, Board Member at Cormedix ( NASDAQ:CRMD ) , was executed on October 28, and reported in the recent SEC filing. What Happened: In a significant move reported in a Form 4 filing with the U.S.
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath
BERKELEY HEIGHTS, N.J., Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- CorMedix Inc. ( Nasdaq: CRMD ) , a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that DefenCath has received an Innovative ...
CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath - Cormedix ( NASDAQ:CRMD )
BERKELEY HEIGHTS, N.J., Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- CorMedix Inc. ( NASDAQ:CRMD ) , a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that DefenCath has received an Innovative ...
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.
Earnings Estimates Rising for CorMedix ( CRMD ) : Will It Gain?
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts See a 68.59% Upside in CorMedix ( CRMD ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 68.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CorMedix ( CRMD ) Surges 19.5%: Is This an Indication of Further Gains?
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
‒ Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million ...
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
ILMN Stock Set to Benefit From the Launch of New BioInsight Division
Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains. it also raises FY26 sales outlook, sending shares higher.
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant ...
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
